Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients

Amy Furman, Joy L. Meier, Robert A. Malmstrom, Julio R. Lopez, Saul Schaefer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Treatment of dyslipidemia in high-risk patients specifies a low-density lipoprotein (LDL) cholesterol >100 mg/dL. The efficacy of higher-potency regimens in clinical practice in patients who have not achieved their LDL goal on generic therapy is not well characterized. The primary objective of this study was to determine the LDL-lowering efficacy of higher-potency strategies (ezetimibe/simvastatin, rosuvastatin, and atorvastatin) in high-risk patients who were switched from simvastatin therapy. Secondary objectives were to evaluate patient adherence to these therapies, determine the efficacy of these interventions on other lipid parameters, and define the incidence of adverse effects. Study Design: Retrospective data analysis derived from the Veterans Affairs Health Care System VISN 21 over a 3-year time period. Methods: Lipid data were assessed prior to and within 2 to 6 months following the conversion from simvastatin. Adherence to therapy was determined by medication refill data. Results: Treatment with ezetimibe/simvastatin resulted in significantly greater reductions in LDL compared with rosuvastatin or atorvastatin (37 vs 25 and 26 mg/dL, respectively; P <0.05). Adherence to therapy was 51% of all patients studied. All treatments significantly lowered total cholesterol, high-density lipoprotein, and triglycerides when compared with simvastatin. There was no difference between treatment groups in the number of adverse events. Conclusions: At the doses used in this population, ezetimibe/simvastatin resulted in greater LDL reductions than rosuvastatin or atorvastatin. The clinical impact of these differences is as yet undetermined.

Original languageEnglish (US)
Pages (from-to)538-544
Number of pages7
JournalAmerican Journal of Managed Care
Volume17
Issue number8
StatePublished - Aug 2011

Fingerprint

Simvastatin
Hyperlipidemias
LDL Lipoproteins
Therapeutics
Veterans Health
Lipids
Rosuvastatin Calcium
Atorvastatin Calcium
Ezetimibe
Patient Compliance
Dyslipidemias
LDL Cholesterol
Retrospective Studies
Cholesterol
Delivery of Health Care
Incidence

ASJC Scopus subject areas

  • Health Policy

Cite this

Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. / Furman, Amy; Meier, Joy L.; Malmstrom, Robert A.; Lopez, Julio R.; Schaefer, Saul.

In: American Journal of Managed Care, Vol. 17, No. 8, 08.2011, p. 538-544.

Research output: Contribution to journalArticle

Furman, Amy ; Meier, Joy L. ; Malmstrom, Robert A. ; Lopez, Julio R. ; Schaefer, Saul. / Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. In: American Journal of Managed Care. 2011 ; Vol. 17, No. 8. pp. 538-544.
@article{ab0fcc86df704fadb70f29da797f9244,
title = "Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients",
abstract = "Objective: Treatment of dyslipidemia in high-risk patients specifies a low-density lipoprotein (LDL) cholesterol >100 mg/dL. The efficacy of higher-potency regimens in clinical practice in patients who have not achieved their LDL goal on generic therapy is not well characterized. The primary objective of this study was to determine the LDL-lowering efficacy of higher-potency strategies (ezetimibe/simvastatin, rosuvastatin, and atorvastatin) in high-risk patients who were switched from simvastatin therapy. Secondary objectives were to evaluate patient adherence to these therapies, determine the efficacy of these interventions on other lipid parameters, and define the incidence of adverse effects. Study Design: Retrospective data analysis derived from the Veterans Affairs Health Care System VISN 21 over a 3-year time period. Methods: Lipid data were assessed prior to and within 2 to 6 months following the conversion from simvastatin. Adherence to therapy was determined by medication refill data. Results: Treatment with ezetimibe/simvastatin resulted in significantly greater reductions in LDL compared with rosuvastatin or atorvastatin (37 vs 25 and 26 mg/dL, respectively; P <0.05). Adherence to therapy was 51{\%} of all patients studied. All treatments significantly lowered total cholesterol, high-density lipoprotein, and triglycerides when compared with simvastatin. There was no difference between treatment groups in the number of adverse events. Conclusions: At the doses used in this population, ezetimibe/simvastatin resulted in greater LDL reductions than rosuvastatin or atorvastatin. The clinical impact of these differences is as yet undetermined.",
author = "Amy Furman and Meier, {Joy L.} and Malmstrom, {Robert A.} and Lopez, {Julio R.} and Saul Schaefer",
year = "2011",
month = "8",
language = "English (US)",
volume = "17",
pages = "538--544",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "8",

}

TY - JOUR

T1 - Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients

AU - Furman, Amy

AU - Meier, Joy L.

AU - Malmstrom, Robert A.

AU - Lopez, Julio R.

AU - Schaefer, Saul

PY - 2011/8

Y1 - 2011/8

N2 - Objective: Treatment of dyslipidemia in high-risk patients specifies a low-density lipoprotein (LDL) cholesterol >100 mg/dL. The efficacy of higher-potency regimens in clinical practice in patients who have not achieved their LDL goal on generic therapy is not well characterized. The primary objective of this study was to determine the LDL-lowering efficacy of higher-potency strategies (ezetimibe/simvastatin, rosuvastatin, and atorvastatin) in high-risk patients who were switched from simvastatin therapy. Secondary objectives were to evaluate patient adherence to these therapies, determine the efficacy of these interventions on other lipid parameters, and define the incidence of adverse effects. Study Design: Retrospective data analysis derived from the Veterans Affairs Health Care System VISN 21 over a 3-year time period. Methods: Lipid data were assessed prior to and within 2 to 6 months following the conversion from simvastatin. Adherence to therapy was determined by medication refill data. Results: Treatment with ezetimibe/simvastatin resulted in significantly greater reductions in LDL compared with rosuvastatin or atorvastatin (37 vs 25 and 26 mg/dL, respectively; P <0.05). Adherence to therapy was 51% of all patients studied. All treatments significantly lowered total cholesterol, high-density lipoprotein, and triglycerides when compared with simvastatin. There was no difference between treatment groups in the number of adverse events. Conclusions: At the doses used in this population, ezetimibe/simvastatin resulted in greater LDL reductions than rosuvastatin or atorvastatin. The clinical impact of these differences is as yet undetermined.

AB - Objective: Treatment of dyslipidemia in high-risk patients specifies a low-density lipoprotein (LDL) cholesterol >100 mg/dL. The efficacy of higher-potency regimens in clinical practice in patients who have not achieved their LDL goal on generic therapy is not well characterized. The primary objective of this study was to determine the LDL-lowering efficacy of higher-potency strategies (ezetimibe/simvastatin, rosuvastatin, and atorvastatin) in high-risk patients who were switched from simvastatin therapy. Secondary objectives were to evaluate patient adherence to these therapies, determine the efficacy of these interventions on other lipid parameters, and define the incidence of adverse effects. Study Design: Retrospective data analysis derived from the Veterans Affairs Health Care System VISN 21 over a 3-year time period. Methods: Lipid data were assessed prior to and within 2 to 6 months following the conversion from simvastatin. Adherence to therapy was determined by medication refill data. Results: Treatment with ezetimibe/simvastatin resulted in significantly greater reductions in LDL compared with rosuvastatin or atorvastatin (37 vs 25 and 26 mg/dL, respectively; P <0.05). Adherence to therapy was 51% of all patients studied. All treatments significantly lowered total cholesterol, high-density lipoprotein, and triglycerides when compared with simvastatin. There was no difference between treatment groups in the number of adverse events. Conclusions: At the doses used in this population, ezetimibe/simvastatin resulted in greater LDL reductions than rosuvastatin or atorvastatin. The clinical impact of these differences is as yet undetermined.

UR - http://www.scopus.com/inward/record.url?scp=80052089507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052089507&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 538

EP - 544

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 8

ER -